Inhibition of Thrombin-catalyzed Factor V Activation by Bothrojaracin

Summary

We have previously identified and characterized a potent and specific thrombin inhibitor, isolated from Bothrops jararaca, named bothrojaracin. Bothrojaracin interacts with the two positively charged recognition sites of thrombin referred to as exosite 1 and exosite 2, whereas it does not interact with the thrombin active site. Consequently, bothrojaracin inhibits thrombin-induced fibrinogen to fibrin conversion and platelet activation, without inhibition of thrombin-catalyzed cleavage of small synthetic substrates. In the present study, we show that bothrojaracin exerts an anticoagulant effect in plasma, illustrated by the prolongation of the aPTT. Using purified proteins, we observed that the anticoagulant effect of bothrojaracin was not only due to the inhibition of fibrinogen to fibrin conversion, but in addition to the inhibition of factor V activation by thrombin. Bothrojaracin decreased the rate of thrombin-catalyzed proteolysis of factor V and concurrently the generation of factor Va cofactor activity measured in a prothrombinase assay. We compared the effect of bothrojaracin with that of ligands binding specifically exosite 1 (hirudin C-terminal peptide SH54-65) or exosite 2 (heparin, prothrombin fragment 2). SH54-65 delayed thrombin catalyzed factor V activation whereas heparin or prothrombin fragment 2 did not. The thrombin derivatives β- and γ-thrombin, which are defective in their exosite 1, but present with a normally exposed exosite 2, had a reduced capacity to activate factor V, which was not further impaired by the exosite 2 ligands, bothrojaracin, heparin or prothrombin fragment 2. Altogether, our results provide further insight into the anticoagulant effect of bothrojaracin showing that it is a potent inhibitor of the feedback activation of factor V by thrombin, and thus of the up-regulation of its own production by thrombin. Inhibition of thrombin-catalyzed factor V activation by bothrojaracin is mainly mediated through the interaction of the inhibitor with thrombin exosite 1, whereas contribution of the interaction with exosite 2 does not appear to play a direct role in factor V recognition by thrombin.

• References

• 1 Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30: 10363-70.
• 2 Ofosu FA, Liu L, Freedman J. Control mechanisms in thrombin generation. Sem Thromb Haemost 1996; 22: 303-8.
• 3 Van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipids and factor VIIIa in the activation of bovin factor X. J Biol Chem 1981; 256: 3433-41.
• 4 Rosing J, Tans G, Govers-Riemslag JWP, Zwaal RFA, Hemker HC. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255: 274-83.
• 5 Fenton JW, Ofosu FA, Moon DG, Maraganore JM. Thrombin structure and function: why thrombin is the primary target for antithrombotics. Blood Coagulation and Fibrinolysis 1991; 2: 69-75.
• 6 Bode W, Turk D, Karshikov A. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human α-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci 1992; 1: 426-71.
• 7 Arni RK, Padmanabhan R, Padmanabhan KP, Wu TP, Tulinsky A. Structures of the noncovalent complexes of human and bovine prothrombin fragment 2 with human PPACK-thrombin. Biochemistry 1993; 32: 4727-37.
• 8 Jandrot-Perrus M, Clemetson KJ, Huisse MG, Guillin MC. Interaction with platelet glycoprotein Ib: effect of glycocalicin on thrombin specificity. Blood 1992; 80: 2781-6.
• 9 Guillin MC, Bezeaud A, Bouton MC, Jandrot-Perrus M. Thrombin specificity. Thromb Haemost 1995; 74: 129-33.
• 10 Naski MC, Fenton JW II, Maraganore JM, Olson ST, Shafer JA. The COOH-terminal domain of hirudin. An exosite-directed competitive inhibitor of the action of α-thrombin on fibrinogen. J Biol Chem 1990; 265: 13484-9.
• 11 Wu Q, Sheehan JP, Tsiang M, Lentz SR, Birktoft JJ, Sadler JE. Single amino acid substitutions dissociate fibrinogen-clotting and thrombomodulin-binding activities of human thrombin. Proc Natl Acad Sci USA 1991; 88: 6775-9.
• 12 Bouton MC, Jandrot-Perrus M, Moog S, Cazenave JP, Guillin MC, Lanza F. Thrombin interaction with a recombinant N-terminal extracellular domain of the thrombin receptor in an acellular system. Biochem J 1995; 305: 635-41.
• 13 Gan ZR, Li Y, Chen Z, Lewis SD, Shafer JA. Identification of basic amino acid residues in thrombin essential for heparin-catalyzed inactivation by antithrombin III. J Biol Chem 1994; 269: 1301-5.
• 14 Sheehan JP, Sadler JE. Molecular mapping of the heparin-binding exosite of thrombin. Proc Natl Acad Sci USA 1994; 91: 5518-22.
• 15 Zingali RB, Jandrot-Perrus M, Guillin MC, Bon C. Bothrojaracin, a new thrombin inhibitor isolated from Bothrops jararaca venom: characterization and mechanism of thrombin inhibition. Biochemistry 1993; 32: 10794-802.
• 16 Arocas V, Zingali RB, Guillin MC, Bon C, Jandrot-Perrus M. Bothrojaracin: a potent two-site-directed thrombin inhibitor. Biochemistry 1996; 35: 9083-9.
• 17 Bezeaud A, Drouet L, Soria C, Guillin MC. Prothrombin Salakta: an abnormal prothrombin characterized by a defect in the active site of thrombin. Thromb Res 1984; 34: 507-18.
• 18 Bezeaud A, Denninger MH, Guillin MC. Interaction of human α-thrombin and γ-thrombin with antithrombin IIII, protein C, and thrombomodulin. Eur J Biochem 1985; 153: 491-6.
• 19 Bezeaud A, Guillin MC. Enzymic and non enzymic properties of human β-thrombin. J Biol Chem 1988; 263: 3576-81.
• 20 Jandrot-Perrus M, Didry D, Guillin MC, Nurden AT. Cross-linking of α-and γ-thrombin to distinct binding sites on human platelets. Eur J Biochem 1988; 174: 359-67.
• 21 Monkovic DD, Tracy PB. Activation of human factor V by factor Xa and thrombin. Biochemistry 1990; 29: 1118-28.
• 22 Guillin MC, Bezeaud A. Thrombin derivatives obtained by autolytic or limited tryptic cleavage. Semin Thromb Hemost 1992; 18: 224-9.
• 23 Rydel TJ, Yin M, Padmanabhan KP, Blankenship DT, Cardin AD, Corria PE, Fenton II JW, Tulinsky A. Crystallographic structure of human γ-thrombin. J Biol Chem 1994; 269: 22000-6.
• 24 Maraganore JM, Chao B, Joseph ML, Jablonski J, Ramachandran KL. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem 1989; 264: 8692-8.
• 25 Prasa D, Svendsen L, Stürzebecher J. The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation. Thromb Haemost 1997; 77: 498-503.
• 26 Lindhout T, Blezer R, Hemker HC. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb Haemost 1990; 64: 464-8.
• 27 Keller FG, Ortel TL, Quinn-Allen MA, Kane WH. Thrombin-catalyzed activation of recombinant human factor V. Biochemistry 1995; 34: 4118-24.
• 28 Esmon CT, Esmon NL, Harris KW. Complex formation between thrombin and thrombomodulin inhibits both thrombin catalyzed fibrin formation and factor V activation. J Biol Chem 1982; 257: 7944-7.
• 29 Pittman DD, Tomkinson KN, Michnick D, Selighsohn U, Kaufman RJ. Posttranslational sulfation of factor V is required for efficient thrombin cleavage and activation and for full procoagulant activity. Biochemistry 1994; 33: 6952-9.
• 30 Esmon CT, Lollar P. Involvement of thrombin anion-binding exosites 1 and 2 in the activation of factor V and factor VIII. J Biol Chem 1996; 271: 13882-7.